Search by Drug Name or NDC
NDC 50458-0543-60 INVOKAMET 150; 1000 mg/1; mg/1 Details
INVOKAMET 150; 1000 mg/1; mg/1
INVOKAMET is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Janssen Pharmaceuticals, Inc.. The primary component is CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE.
Product Information
NDC | 50458-0543 |
---|---|
Product ID | 50458-543_004d0398-3384-8623-e063-6394a90aaae7 |
Associated GPIs | 27996002200350 |
GCN Sequence Number | 072589 |
GCN Sequence Number Description | canagliflozin/metformin HCl TABLET 150-1000MG ORAL |
HIC3 | C4E |
HIC3 Description | ANTIHYPERGLYCEMIC-SGLT2 INHIBITOR-BIGUANIDE COMBS. |
GCN | 36859 |
HICL Sequence Number | 041287 |
HICL Sequence Number Description | CANAGLIFLOZIN/METFORMIN HCL |
Brand/Generic | Brand |
Proprietary Name | INVOKAMET |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | canagliflozin and metformin hydrochloride |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, FILM COATED |
Route | ORAL |
Active Ingredient Strength | 150; 1000 |
Active Ingredient Units | mg/1; mg/1 |
Substance Name | CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE |
Labeler Name | Janssen Pharmaceuticals, Inc. |
Pharmaceutical Class | Biguanide [EPC], Biguanides [CS], P-Glycoprotein Inhibitors [MoA], Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA204353 |
Listing Certified Through | 2024-12-31 |
Package
NDC 50458-0543-60 (50458054360)
NDC Package Code | 50458-543-60 |
---|---|
Billing NDC | 50458054360 |
Package | 60 TABLET, FILM COATED in 1 BOTTLE (50458-543-60) |
Marketing Start Date | 2014-08-08 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 9.5189 |
Pricing Unit | EA |
Effective Date | 2023-11-22 |
NDC Description | INVOKAMET 150-1,000 MG TABLET |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 2 |
Classification for Rate Setting | B |
As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis